{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:50Z","timestamp":1786118930838,"version":"build-2736575974"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1097\/iae.0b013e318176de48","type":"journal-article","created":{"date-parts":[[2008,9,3]],"date-time":"2008-09-03T08:00:13Z","timestamp":1220428813000},"page":"1053-1060","source":"Crossref","is-referenced-by-count":117,"title":["LONG-TERM EFFECT OF INTRAVITREAL BEVACIZUMAB (AVASTIN) IN PATIENTS WITH CHRONIC DIFFUSE DIABETIC MACULAR EDEMA"],"prefix":"10.1097","volume":"28","author":[{"given":"DANIEL","family":"KOOK","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ATMIN","family":"WOLF","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"THOMAS","family":"KREUTZER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALJOSCHA","family":"NEUBAUER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RUPERT","family":"STRAUSS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHAEL","family":"ULBIG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANSLEM","family":"KAMPIK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHRISTOS","family":"HARITOGLOU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210130","doi-asserted-by":"crossref","first-page":"C11","DOI":"10.2337\/diacare.21.3.C11","article-title":"Diabetes in America: epidemiology and scope of the problem.","volume":"21","author":"Harris","year":"1998","journal-title":"Diabetes Care"},{"key":"R2-4-20210130","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1056\/NEJM200002103420603","article-title":"Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive insulin therapy.","volume":"342","year":"2000","journal-title":"N Engl J Med"},{"key":"R3-4-20210130","first-page":"331","article-title":"Evidence-based Ophthalmology.","author":"Richter","year":"2004"},{"key":"R4-4-20210130","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1.","volume":"103","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"R5-4-20210130","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen.","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"key":"R6-4-20210130","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1126\/science.6823562","article-title":"Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.","volume":"219","author":"Senger","year":"1983","journal-title":"Science"},{"key":"R7-4-20210130","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1167\/iovs.02-0807","article-title":"VEGF164 is proinflammatory in the diabetic retina.","volume":"44","author":"Ishida","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R8-4-20210130","first-page":"1774","article-title":"Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor.","volume":"50","author":"Senger","year":"1990","journal-title":"Cancer Res"},{"key":"R9-4-20210130","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen.","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"key":"R10-4-20210130","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.2479987","article-title":"Vascular permeability factor, an endothelial cell mitogen related to PDGF.","volume":"246","author":"Keck","year":"1989","journal-title":"Science"},{"key":"R11-4-20210130","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0002-9394(14)72066-5","article-title":"Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes.","volume":"122","author":"Frank","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"R12-4-20210130","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/bjo.81.2.154","article-title":"Increased expression of angiogenic growth factors in age-related maculopathy.","volume":"81","author":"Kliffen","year":"1997","journal-title":"Br J Ophthalmol"},{"key":"R13-4-20210130","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ophtha.2005.10.030","article-title":"Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema.","volume":"113","author":"Funatsu","year":"2006","journal-title":"Ophthalmology"},{"key":"R14-4-20210130","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration.","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"key":"R15-4-20210130","first-page":"361","article-title":"Ranibizumab: Phase III clinical trial results.","volume":"19","author":"Rosenfeld","year":"2006","journal-title":"Ophthalmol Clin North Am"},{"key":"R16-4-20210130","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"R17-4-20210130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1053\/j.seminoncol.2005.06.003","article-title":"The role of bevacizumab as first-line therapy for colon cancer.","volume":"32","author":"Marshall","year":"2005","journal-title":"Semin Oncol"},{"key":"R18-4-20210130","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study.","volume":"112","author":"Michels","year":"2005","journal-title":"Ophthalmology"},{"key":"R19-4-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2006.02.037","article-title":"Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.","volume":"142","author":"Bashshur","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R20-4-20210130","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R22-4-20210130","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00006982-200603000-00003","article-title":"Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment.","volume":"26","author":"Maturi","year":"2006","journal-title":"Retina"},{"key":"R23-4-20210130","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00006982-200603000-00001","article-title":"Testing intravitreal toxicity of bevacizumab (Avastin).","volume":"26","author":"Manzano","year":"2006","journal-title":"Retina"},{"key":"R24-4-20210130","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3928\/1542-8877-20050701-15","article-title":"Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion.","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R25-4-20210130","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.ophtha.2006.11.028","article-title":"Intravitreal bevacizumab for treatment of uveitic macular edema.","volume":"114","author":"Cordero Coma","year":"2007","journal-title":"Ophthalmology"},{"key":"R26-4-20210130","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00006982-200603000-00005","article-title":"Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study.","volume":"26","author":"Iturralde","year":"2006","journal-title":"Retina"},{"key":"R27-4-20210130","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2005.06.007","article-title":"Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.","volume":"112","author":"Cunningham","year":"2005","journal-title":"Ophthalmology"},{"key":"R28-4-20210130","first-page":"992","article-title":"VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group. Pegaptanib sodium for neovascular age-related macular degeneration. Two-year safety results of the two prospective, multicenter, controlled clinical trials.","volume":"113","author":"D'Amico","year":"2006","journal-title":"Ophthalmology"},{"key":"R29-4-20210130","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.ophtha.2006.04.033","article-title":"A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema.","volume":"113","author":"Chun","year":"2006","journal-title":"Ophthalmology"},{"key":"R30-4-20210130","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","article-title":"Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"R31-4-20210130","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R32-4-20210130","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/01.iae.0000247165.38655.bf","article-title":"Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.","volume":"26","author":"Haritoglou","year":"2006","journal-title":"Retina"},{"key":"R33-4-20210130","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/01.iae.0000246884.76018.63","article-title":"Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).","volume":"26","author":"Jorge","year":"2006","journal-title":"Retina"},{"key":"R34-4-20210130","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ophtha.2006.12.028","article-title":"Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.","volume":"114","author":"Arevalo","year":"2007","journal-title":"Ophthalmology"},{"key":"R35-4-20210130","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ajo.2007.02.048","article-title":"Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes.","volume":"144","author":"Yanyali","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R36-4-20210130","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0161-6420(13)38011-7","article-title":"Early photocoagulation for diabetic retinopathy. ETDRS report 9.","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"key":"R37-4-20210130","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0002-9440(10)64869-9","article-title":"Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo.","volume":"160","author":"Joussen","year":"2002","journal-title":"Am J Pathol"},{"key":"R38-4-20210130","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.ophtha.2007.05.057","article-title":"Bevacizumab (Avastin) improves peripheral retinal ischemia in diabetic retinopathy.","volume":"114","author":"Neubauer","year":"2007","journal-title":"Ophthalmology"},{"key":"R39-4-20210130","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/IAE.0b013e31815ec261","article-title":"Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.","volume":"27","author":"Soheilian","year":"2007","journal-title":"Retina"},{"key":"R40-4-20210130","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2007.05.062","article-title":"A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema.","volume":"114","year":"2007","journal-title":"Ophthalmology"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006982-200809000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:04:23Z","timestamp":1786035863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006982-200809000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e318176de48","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}